ProCE Banner Activity

SOLO-1: OS With 7-Yr Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib

Slideset Download
Conference Coverage
The 7-year follow-up from SOLO-1 shows continued survival benefit for patients with newly diagnosed advanced ovarian cancer who were treated with maintenance olaparib for up to 2 years vs placebo.

Released: September 15, 2022

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp